A medicine called enzalutamide 40 mg capsule, sold under the brand name Xtandi, is used to treat metastatic castration-resistant prostate cancer, which is an advanced form of prostate cancer. By inhibiting androgen receptors, it prevents androgens like testosterone from stimulating the growth of prostate cancer cells. Enzalutamide greatly improves patients' quality of life by slowing down the disease's course, increasing survival rates, and assisting with symptom relief by interfering with these signals.